Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy
Authors
Keywords
CAI, PD-1, IFN-, IDO1, AhR
Journal
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-11
DOI
10.1186/s40425-019-0725-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IDO1 in cancer: a Gemini of immune checkpoints
- (2018) Lijie Zhai et al. Cellular & Molecular Immunology
- PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules
- (2018) Qiaohong Geng et al. CURRENT PHARMACEUTICAL DESIGN
- The application of CAR-T cell therapy in hematological malignancies: Advantages and challenges
- (2018) Zijun Zhao et al. Acta Pharmaceutica Sinica B
- Immunotherapy of cancers comes of age
- (2017) Hila Yousefi et al. Expert Review of Clinical Immunology
- Carboxyamidotriazole Synergizes with Sorafenib to Combat Non–Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis
- (2017) Chen Chen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Carboxyamidotriazole alleviates muscle atrophy in tumor-bearing mice by inhibiting NF-κB and activating SIRT1
- (2017) Chen Chen et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Carboxyamidotriazole inhibits oxidative phosphorylation in cancer cells and exerts synergistic anti-cancer effect with glycolysis inhibition
- (2016) Rui Ju et al. CANCER LETTERS
- Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
- (2015) Xiangjiao Meng et al. CANCER TREATMENT REVIEWS
- Big opportunities for small molecules in immuno-oncology
- (2015) Jerry L. Adams et al. NATURE REVIEWS DRUG DISCOVERY
- Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
- (2015) Kim C. Ohaegbulam et al. TRENDS IN MOLECULAR MEDICINE
- The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
- (2013) Li Shi et al. Journal of Hematology & Oncology
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
- (2012) M. Platten et al. CANCER RESEARCH
- Why tumours eat tryptophan
- (2011) George C. Prendergast NATURE
- TNFR1 Signaling and IFN-γ Signaling Determine whether T Cells Induce Tumor Dormancy or Promote Multistage Carcinogenesis
- (2008) Nele Müller-Hermelink et al. CANCER CELL
- Anti-Inflammatory and Analgesic Potency of Carboxyamidotriazole, a Tumorostatic Agent
- (2008) L. Guo et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51)
- (2007) Elizabeth A. Johnson et al. LUNG CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now